$CING SEC Filings

Filed On	Filing
02 Oct 2026	Form 4: Silva Raul R., EVP and CSO Granted 4,293 Stock Option (right to Buy)
02 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers This AMENDMENT NO. 2 is made and effective as of September 30, 2026 by and between CINGULATE THERAPEUTICS LLC, a Delaware Limited Liability Company, whose principal address is 1901 W. 47th Place, 3rd Floor, Kansas City, KS 66205 (the “Co...
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
23 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
20 Jul 2026	Form 4: Schaffer Shane J., Director Granted 295,000 Stock Option (right to Buy)
20 Jul 2026	Form 4: Downey Bryan Wade, EVP & Chief Commercial Officer Granted 100,000 Stock Option (right to Buy)
20 Jul 2026	Form 4: Lawrence Bryan Jay, Director Granted 20,000 Stock Option (right to Buy)
20 Jul 2026	Form 4: Brams Matthew, EVP and Chief Medical Officer Granted 80,000 Stock Option (right to Buy)
20 Jul 2026	Form 4: Hargroves Thomas Jeffrey, Director Granted 20,000 Stock Option (right to Buy)
20 Jul 2026	Form 4: Callahan Jennifer L., EVP and CFO Granted 60,000 Stock Option (right to Buy)
20 Jul 2026	Form 4: Werth Peter J., Director Granted 20,000 Stock Option (right to Buy)
20 Jul 2026	Form 4: Silva Raul R., EVP and CSO Granted 80,000 Stock Option (right to Buy)
15 Jul 2026	S-8
14 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
02 Jul 2026	Form 4: Silva Raul R., EVP and CSO Granted 3,885 Stock Option (right to Buy)
02 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
16 Jun 2026	8-K: Regulation FD Disclosure
08 Jun 2026	Form 4: Hargroves Thomas Jeffrey, Director Bought 97,276 shares ($490K) · Acquired 77,821 Warrant to Purchase Common Stock (Open Market Purchase) ($7.78K) · Granted 15,000 Stock Option (right to Buy)
08 Jun 2026	Form 3: Hargroves Thomas Jeffrey, Director Holds 192 shares of Common Stock

Comments